Loading, Please Wait...
TUCSON, Ariz., Feb. 21, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the quarter and year ended December 31, 2018 after the market close on Thursday, March 7, 2019. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.
|Conference Call & Webcast Details|
|Thursday, March 7
4:30pm Eastern Time
HTG is focused on advancing precision medicine. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options.
Ashley R. Robinson
LifeSci Advisors, LLC
Phone: (617) 535-7742